Boosting treatment stabilization in patients of amphetamine-type stimulant use disorder |
| |
| Institution: | 1. Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran;2. The Kirby Institute, UNSW Sydney, Sydney, Australia;3. Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran;4. Iranian Center for Communicable Diseases Control, Ministry of Health & Medical Education, Tehran, Iran;5. Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Islamic Republic of Iran;6. Mental Health research Center, Iran University of Medical Sciences, Tehran, Iran;7. Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran;1. Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA;2. Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Affairs Healthcare System, North Little Rock, AR 72205, USA;3. VA South Central Mental Illness Research, Education, and Clinical Center, Central Arkansas Veterans Healthcare System (CAVHS), North Little Rock, AR 72205, USA;4. Center for Innovation to Implementation, Veterans Affairs (VA) Health Care System, Menlo Park, CA 94025, USA;5. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA;6. College of Public Health, Department of Health Behavior and Health Education, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA;7. Department of Psychology and Counseling, University of Central Arkansas, Conway, AR 72035, USA;1. Institute of Applied Mathematics, University of British Columbia, 1984 Mathematics Road, Vancouver, BC V6T 1Z2, Canada;2. British Columbia Centre for Disease Control, 655W 12th Avenue, Vancouver, BC V5Z 4R4, Canada;3. Ministry of Mental Health and Addictions, PO Box 9672 Stn Prov Govt, Victoria, BC V8W 9P6, Canada;1. Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA;2. Department of Psychology and Counseling, University of Central Arkansas, Conway, AR 72035, USA;3. Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Affairs Healthcare System, North Little Rock, AR 72205, USA;4. VA South Central Mental Illness Research, Education, and Clinical Center, Central Arkansas Veterans Healthcare System (CAVHS), North Little Rock, AR 72205, USA;5. Center for Innovation to Implementation, Veterans Affairs (VA) Health Care System, Menlo Park, CA 94025, USA;6. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA;7. College of Public Health, Department of Health Behavior and Health Education, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA |
| |
| Abstract: | BackgroundTo investigate boosting effects on treatment stabilization in the mandatory treatment modality for patients of amphetamine-type stimulant use disorder.MethodsThis is a retrospective follow-up study over a period from January 2013 to December 2018. We analyzed 425 patients of amphetamine-type stimulant use disorder under mandating treatments. Treatment stabilization for a given patient was defined once 4 negative urinalysis had been observed. We developed a dynamic monitoring model of boosting effects informed by the available data, specifically the number of negative urine samples required to reach stabilization, the sum of urinalyses done at the time when the given number of negative urine samples had been observed and who the patient was. To represent the simulated population, a Monte Carlo method was used to generate p-values from 1000 experiments conducted on a computer.ResultsIn the observed samples, the probability of 4 negative results in urinalysis from 4 outpatient visits was 75.5%. In comparison, the probability for achieving 4th negative results in urinalysis over 4 visits from negative binominal distribution was 57.3%, and from the computer simulation, 49.8%. The observed samples had significantly higher probability of achieving 4 negative results in urinalysis over 4 outpatient visits (p < 0.001).ConclusionsThe mandatory treatment modality boosted treatment stabilization for patients of amphetamine-type stimulant use disorder. The major benefit of using the monitoring model is the ability to monitor boosting effects of stabilization. Results supported the effectiveness of this mandatory treatment modality and can be implemented in deferred-prosecution based treatment modality. |
| |
| Keywords: | Amphetamine-type stimulant Treatment stabilization Negative binominal distribution |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
